Compare · MYO vs ZBH
MYO vs ZBH
Side-by-side comparison of Myomo Inc. (MYO) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $16.05B, about 463.1x MYO ($34.7M).
- Over the past year, MYO is down 81.7% and ZBH is down 19.0% - ZBH leads by 62.7 points.
- MYO has been more active in the news (11 items in the past 4 weeks vs 7 for ZBH).
- ZBH has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $0.89+2.96%
- $82.91+0.62%
- Market cap
- $34.7M
- $16.05B
- 1M return
- +32.92%
- -8.90%
- 1Y return
- -81.66%
- -18.95%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 11
- 7
- Recent ratings
- 3
- 25
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest MYO
- Myomo to Report First Quarter 2026 Financial Results on May 7
- Amendment: SEC Form 10-K/A filed by Myomo Inc.
- Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
- SEC Form 4 filed by Febbo William J
- SEC Form 3 filed by new insider Febbo William J
- Myomo Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Myomo Appoints William J Febbo to its Board of Directors
- Amendment: SEC Form 4 filed by Gudonis Paul R
- SEC Form 4 filed by Henry David A
- SEC Form 4 filed by Gudonis Paul R
Latest ZBH
- SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zimmer Biomet Announces First Quarter 2026 Financial Results
- Zimmer Biomet Announces Chief Financial Officer Transition
- Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
- Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
- SEC Form 4 filed by Noor Jehanzeb
- SEC Form 4 filed by Jafry Syed A.
- SEC Form 4 filed by Kolli Sreelakshmi